<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120753</url>
  </required_header>
  <id_info>
    <org_study_id>DWJ1351_P401</org_study_id>
    <nct_id>NCT04120753</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (Olmesartan 20 mg/Amlodipine 5 mg/Rosuvastatin 5 or 10 mg) in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease</brief_title>
  <official_title>A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (Olmesartan 20 mg/Amlodipine 5 mg/Rosuvastatin 5 or 10 mg) in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of OLOMAX Tab (20/5/5mg,
      20/5/10mg) in Hypertension Patients with Low-Intermediate Risk for Cardiovascular Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in measured LDL-C (mLDL-C)</measure>
    <time_frame>After 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in measured LDL-C (mLDL-C)</measure>
    <time_frame>After 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in cLDL-C</measure>
    <time_frame>After 4 weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in lipid profile(without LDL-C)</measure>
    <time_frame>After 4 weeks and 8 weeks</time_frame>
    <description>Total cholesterol, HDL-C, Triglyceride, mLDL-C/HDL-C ratio, hs-CRP, Apo A-1, Apo B, Apo B/Apo A-1 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reached in mLDL-C &lt; 70mg/dL</measure>
    <time_frame>After 4 weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reached in mLDL-C &lt; 100mg/dL</measure>
    <time_frame>After 4 weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes and rate of change in sitSBP</measure>
    <time_frame>After 4 weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes and rate of change in sitDBP</measure>
    <time_frame>After 4 weeks and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reached the therapeutic goal</measure>
    <time_frame>After 8 weeks</time_frame>
    <description>sitSBP&lt;140mmHg and sitDBP&lt;90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes and rate of change in glucose metabolic profile</measure>
    <time_frame>After 4 weeks and 8 weeks</time_frame>
    <description>Fasting plasma glucose (FPG), Fructosamine, HbA1c</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OLOMAX 20/5/5mg</intervention_name>
    <description>Tablets, Oral, QD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OLOMAX 20/5/10mg</intervention_name>
    <description>Tablets, Oral, QD</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan 20 mg/Amlodipine 5 mg</intervention_name>
    <description>Tablets, Oral, QD</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both man and woman who is over 19 years old

          -  Patients with hypertension

          -  Persons with mLDL ≥ 130mg/dL (low risk for cardiovascular disease) or mLDL ≥ 100mg/dL
             (intermediate risk for cardiovascular disease)

          -  Written informed consent

        Exclusion Criteria:

          -  Patient with hypersensitivity Olmesartan, Amlodipine, Rosuvastatin, dihydropyridine

          -  Who disagreed to perform effective contraception during the clinical trial

          -  Orthostatic hypotension with symptoms

          -  Secondary hypertension and suspected secondary hypertension

          -  Creatinine clearance &lt; 30mL/min

          -  AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x ULN (upper
             limit of normal range)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lee</last_name>
    <phone>02-550-8736</phone>
    <email>solee084@daewoong.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shin</last_name>
    <phone>02-550-8442</phone>
    <email>jmshin134@daewoong.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Daewoong pharmatceutical</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwon</last_name>
      <phone>02-2059-1838</phone>
      <email>gykwon277@daewoong.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

